Biomarkers Are Changing Alzheimer’s Research, Trial Execution Must Catch Up
Biomarkers are changing what is possible in Alzheimer’s clinical trials. They are helping sponsors identify patients earlier, define disease biology more precisely and design more targeted studies.
But as Alzheimer’s research becomes more biomarker-led, trial execution is becoming more complex. Recruitment, patient identification, protocol design, site readiness and participant burden all need to be considered differently.
Moderated by Meredith Landry (Citeline), this roundtable brought together experts from Southern Star Research, Alzheimer’s Research UK, PLL Therapeutics and Irvine Clinical Research to discuss how biomarker advances are reshaping Alzheimer’s trial planning and execution.
The report explores why scientific progress alone is not enough to address the practical challenges facing Alzheimer’s development, and what sponsors need to consider as studies become more targeted, operationally demanding and regionally complex.
The discussion considers:
- How biomarker advances are changing patient identification and recruitment
- Why protocol complexity and participant burden need closer attention
- How regional factors can influence Alzheimer’s trial execution across Australia and APAC
For sponsors planning Alzheimer’s clinical trials, the discussion highlights why execution needs to keep pace with the science.
To explore the insights shared by Dr Brendon Boot, Daniel Evans, Susan Kohlhaas, Pierre Morgon and Dr Edward Zamrini, download the full executive summary.